What they were paid
Allogene Therapeutics Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $58,576 | $123,066 | — | — | $181,642 |
| FY2024 | $47,500 | $0 | $298,650 | $0 | $346,150 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Allogene Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001628280-26-028948, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Allogene Therapeutics pays directors a $40,000 cash retainer.
Committees
FY2025 · as the proxy prints themAudit · Research and Development
The rest of the Allogene Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Arie Belldegrun, M.D | Chair of the Board | $4,077,520 |
| David Bonderman | Independent Director | $0 |
| David Chang, M.D., Ph.D | Director | $0 |
| Deborah Messemer | Independent Director | $193,066 |
| Elizabeth Barrett | Independent Director | $183,066 |
| Franz Humer, Ph.D | Lead Independent Director | $274,879 |
| John DeYoung | Independent Director | $0 |
| Joshua Kazam | Director | $170,066 |
| Owen Witte, M.D | Independent Director | $193,066 |
| Todd Sisitsky | Independent Director | $0 |
| Vicki Sato, Ph.D | Independent Director | $182,224 |
The full Allogene Therapeutics compensation record
free company briefThis page is one director within Allogene Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat